CIK 0001384101 · Large accelerated filer
VERACYTE, INC.
Sign in to watch- Ticker
- VCYT
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205455398
- Phone
- (650) 243-6300
- Business address
- 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- CALDEROME INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,858,989
- in 9 filings, $2.9M under 10b5-1 plans
Net −$2,858,989. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-06 | McGuire Annie SVP, General Counsel | Grant or award | +26,314 | 153,912 | ||
| 2026-03-06 | Chambers Rebecca Chief Financial Officer | Grant or award | +36,181 | 167,377 | ||
| 2026-03-06 | Chambers Rebecca Chief Financial Officer | Grant or award | +13,157 | 180,534 | ||
| 2026-03-06 | Febbo Phillip G. Chief Scientific & Med Officer | Grant or award | +29,603 | 146,949 | ||
| 2026-03-06 | Febbo Phillip G. Chief Scientific & Med Officer | Grant or award | +6,578 | 153,527 | ||
| 2026-03-06 | Wygant Jonathan VP, Chief Accounting Officer | Grant or award | +10,525 | 45,434 | ||
| 2026-03-06 | Stapley Marc Chief Executive Officer | Grant or award | +92,099 | 449,653 | ||
| 2026-03-04 | Leite John Chief Commercial Officer-CLIA | Sale 10b5-1 | −5,260 | $35.19 | $185K | 107,580 |
| 2026-03-04 | McGuire Annie SVP, General Counsel | Sale 10b5-1 | −4,994 | $35.29 | $176K | 96,370 |
| 2026-03-04 | McGuire Annie SVP, General Counsel | Sale 10b5-1 | −1,664 | $36.34 | $60K | 94,706 |
| 2026-03-04 | Chambers Rebecca Chief Financial Officer | Sale 10b5-1 | −4,400 | $35.55 | $156K | 145,137 |
| 2026-03-04 | Chambers Rebecca Chief Financial Officer | Sale 10b5-1 | −13,941 | $36.33 | $506K | 131,196 |
| 2026-03-04 | Stapley Marc Chief Executive Officer | Sale 10b5-1 | −19,244 | $35.56 | $684K | 383,833 |
| 2026-03-04 | Stapley Marc Chief Executive Officer | Sale 10b5-1 | −26,279 | $36.28 | $953K | 357,554 |
| 2026-03-02 | Leite John Chief Commercial Officer-CLIA | Shares withheld for taxes | −7,517 | $36.01 | $271K | 112,840 |
| 2026-03-02 | McGuire Annie SVP, General Counsel | Shares withheld for taxes | −6,902 | $36.01 | $249K | 101,364 |
| 2026-03-02 | Chambers Rebecca Chief Financial Officer | Shares withheld for taxes | −7,234 | $36.01 | $260K | 149,537 |
| 2026-03-02 | Febbo Phillip G. Chief Scientific & Med Officer | Shares withheld for taxes 10b5-1 | −6,035 | $36.01 | $217K | 130,771 |
| 2026-03-02 | Febbo Phillip G. Chief Scientific & Med Officer | Sale 10b5-1 | −13,425 | $36.16 | $485K | 117,346 |
| 2026-03-02 | Wygant Jonathan VP, Chief Accounting Officer | Shares withheld for taxes | −3,006 | $36.01 | $108K | 34,909 |
Page 4 of 9 · 168 trades